Microdosing has become something of a wellness trend in recent years, gathering traction in Australia and overseas.
Psychedelics
Cashed-Up Psychedelic Stocks Well Prepared For Adverse Market Conditions
Psychedelic stocks have been hammered in recent weeks by general selling pressures on tech stocks. But with corporate coffers full, these companies can weather the storm.
Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement
Institutional interest in psychedelics-based TBI research increases, as Wesana closes an oversubcribed CAD$16.1 million financing.
Northampton City Council seeks to decriminalize psychedelic drugs, urge police make possession low enforcement priority
Efforts are underway to make pursuing criminal charges for possession of psychedelics less of a priority in one Western Massachusetts community.
MINDCURE (CSE: MCUR | OTC: MCURF) Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients
Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market, Projected To Reach $56 Billion By 2025 And The Global Psychedelic Market Projected To Reach Over $7.5 Billion By 20281
MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with the SEC under MJDS
MindMed files a "Base Shelf Prospectus" with the SEC.
MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD ($203 million CAD) to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform
MindMed announces its year-end results for 2020, cash-on-hand at US$161 million, including a total cash burn for 2020 of US$24.2 million.
Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe
Cybin announces senior management changes as it moves into the next stage of its evolution.
Why Dollar-Cost Averaging Makes Sense For Psychedelic Stocks
Psychedelic stocks have been battered by general market headwinds in recent weeks. Uncertainty could persist. How do investors allocate capital?
Lobe Sciences Added to Horizons Psychedelic Stock Index ETF
Lobe Sciences becomes the latest addition to the Horizons psychedelics ETF (PSYK).
The First Psychedelic Medicine Clinic Opens in Minnesota
The growing rates of depression, anxiety, and other mental health illnesses have contributed to a national mental health crisis in the United States and call for new and unconventional treatment options.
Case report: Consumption of psilocybin-containing mushrooms results in amelioration of OCD symptoms
Approximately 2.3% of adults will suffer from symptoms of Obsessive-Compulsive Disorder at some point in their life.
Lab expansion project in Nanaimo to aid magic mushroom, psychedelics research
A Nanaimo lab site expansion project will strengthen the facility’s magic mushroom research, say company executives.
The COVID Conundrum For Psychedelic Stocks
The COVID pandemic is making the need for psychedelic drugs and the commercial potential of the industry much greater. But there is a catch.
Traumatic Brain Injury (TBI): Six Psychedelics Companies Target $120 Billion Market
One huge market. Six horses in the race (so far). Lots of prize money to go around.